EPZ031686是一种口服活性SMYD3抑制剂,具有高效性,可用于癌症研究。

[1] Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, West K, Foley M, Waters NJ, Kuntz KW, Wigle TJ, Scott MP, Copeland RA, Smith JJ, Chesworth R. Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Med Chem Lett. 2015 Aug 27,7(2):134-8. doi: 10.1021/acsmedchemlett.5b00272. PMID: 26985287, PMCID: PMC4753551.